Schrödinger

Schrödinger is a 35-year veteran of computational chemistry and physics-based molecular simulation, with software used by virtually every major pharmaceutical company globally. Named for the Austrian physicist Erwin Schrödinger (the Nobel laureate whose wave equation underlies quantum chemistry), the company was founded in 1990 by Richard Friesner and others and went public on NASDAQ as SDGR in 2020. Market capitalization is approximately $2.5 billion as of 2026, with FY2024 software revenue around $200 million plus drug-discovery collaboration revenue around $70 million.

The Schrödinger Suite is the company's core software platform — a comprehensive set of tools for computational chemistry covering molecular dynamics (Desmond), free-energy perturbation (FEP+), de novo design, virtual screening, ligand binding analysis, and protein structure prediction. The platform is the de-facto standard for physics-based drug-design workflows and is increasingly augmented with machine-learning capabilities (active-learning-driven FEP+ workflows, generative-AI molecular design via the LiveDesign collaboration platform, and Schrödinger's own AI-augmented force fields).

Beyond software, Schrödinger has built a drug-discovery business that combines its computational platform with traditional medicinal chemistry. The company has spun out portfolio companies including Nimbus Therapeutics (ALS, autoimmune; partial sale to Takeda) and Morphic Holding (which was acquired by Eli Lilly for $3.2 billion in 2024 for its IBD therapeutic). Schrödinger maintains an internal pipeline of small-molecule programs in oncology and other areas, plus collaboration deals with Bristol-Myers Squibb, Otsuka, Sanofi, Bayer, and others. The company has also expanded into materials-science applications — battery materials, OLED design, catalyst discovery — leveraging the same physics-based + ML platform that powers its drug-discovery work.